Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CMA1 | P23946 | 2/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 2/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | KLK7 | P49862 | 1/20 | 0.37 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.37 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.37 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20701812 | 1.00 | ACE (0.41) | ACEKMT2ACMA1ITGB3ITGA2B | |
| SCHEMBL20701811 | 1.00 | ACE (0.41) | ACEKMT2ACMA1ITGB3ITGA2B | |
| SCHEMBL20986949 | 0.87 | GZMB (0.38) | KMT2ACMA1ITGB3ITGA2BREN | |
| SCHEMBL20701553 | 0.86 | CTSL (0.46) | ACECMA1ITGB3ITGA2BCTSL | |
| SCHEMBL20701559 | 0.86 | CTSL (0.46) | ACECMA1ITGB3ITGA2BCTSL | |
| SCHEMBL20701557 | 0.86 | CTSL (0.46) | ACECMA1ITGB3ITGA2BCTSL | |
| SCHEMBL20701563 | 0.86 | CTSL (0.46) | ACECMA1ITGB3ITGA2BCTSL | |
| SCHEMBL18103810 | 0.80 | ACE (0.42) | ACEKMT2ACMA1CTSLCTSB | |
| SCHEMBL18103807 | 0.80 | ACE (0.42) | ACEKMT2ACMA1CTSLCTSB | |
| SCHEMBL17446707 | 0.78 | CTSD (0.51) | KMT2ACTSLCTSBCTSSREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3186270-B1 | CYCLIC UREA COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC (CA) | 2020-02-19 | — | — | EP | disclosed |
| US-10537652-B2 | Cyclic urea compounds as granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2020-01-21 | — | — | US | disclosed |
| US-20190151484-A2 | CYCLIC UREA COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2019-05-23 | — | — | US | disclosed |
| US-20190038602-A1 | GRANZYME B INHIBITOR FORMULATIONS AND METHODS FOR THE TREATMENT OF BURNS | VIDA THERAPEUTICS, INC. (CA) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190038602-A1 | GRANZYME B INHIBITOR FORMULATIONS AND METHODS FOR THE TREATMENT OF BURNS | GZMB, CTSB, SERPINB1 | ACE 1309/4885KMT2A 4848/4885CMA1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.